Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria M Rubinstein

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 11, 2022
Management of patients with early-stage ovarian clear cell carcinoma: risk stratification and fertility conservationBeryl Manning-Geist, Sushmita Gordhandas, Anjelica Hodgson, et al.
Gynecologic Oncology|November 3, 2020
A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancersMaria M Rubinstein, Rachel N Grisham, Karen Cadoo, et al.
Cancer|December 28, 2019
Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathwayMaria M Rubinstein, David M Hyman, Imogen Caird, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2025
ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous CarcinomaJoyce F Liu, Nicoletta Colombo, Amit M Oza, et al.
Gynecologic Oncology|December 13, 2022
Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 studyMaria M Rubinstein, Eric Rios Doria, Jason Konner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2024
A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial CancerAngela K Green, Qin Zhou, Alexia Iasonos, et al.
Gynecologic Oncology|November 24, 2019
Clinical outcomes of patients with POLE mutated endometrioid endometrial cancerMarina Stasenko, Irina Tunnage, Charles W Ashley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2026
A Phase II Trial of Olaparib Plus Pembrolizumab in Patients with Recurrent Copy-Number High/p53-Abnormal Endometrial CancerMaria M Rubinstein, Jennifer Y Ge, Qin Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 18, 2022
Microsatellite Instability-High Endometrial Cancers with MLH1 Promoter Hypermethylation Have Distinct Molecular and Clinical ProfilesBeryl L Manning-Geist, Ying L Liu, Kelly A Devereaux, et al.
Journal for Immunotherapy of Cancer|June 13, 2025
Phase II study of rucaparib and nivolumab in patients with leiomyosarcomaSujana Movva, Kenneth Seier, Martina Bradic, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 11, 2022
Management of patients with early-stage ovarian clear cell carcinoma: risk stratification and fertility conservationBeryl Manning-Geist, Sushmita Gordhandas, Anjelica Hodgson, et al.
Gynecologic Oncology|November 3, 2020
A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancersMaria M Rubinstein, Rachel N Grisham, Karen Cadoo, et al.
Cancer|December 28, 2019
Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathwayMaria M Rubinstein, David M Hyman, Imogen Caird, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2025
ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous CarcinomaJoyce F Liu, Nicoletta Colombo, Amit M Oza, et al.
Gynecologic Oncology|December 13, 2022
Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 studyMaria M Rubinstein, Eric Rios Doria, Jason Konner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2024
A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial CancerAngela K Green, Qin Zhou, Alexia Iasonos, et al.
Gynecologic Oncology|November 24, 2019
Clinical outcomes of patients with POLE mutated endometrioid endometrial cancerMarina Stasenko, Irina Tunnage, Charles W Ashley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2026
A Phase II Trial of Olaparib Plus Pembrolizumab in Patients with Recurrent Copy-Number High/p53-Abnormal Endometrial CancerMaria M Rubinstein, Jennifer Y Ge, Qin Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 18, 2022
Microsatellite Instability-High Endometrial Cancers with MLH1 Promoter Hypermethylation Have Distinct Molecular and Clinical ProfilesBeryl L Manning-Geist, Ying L Liu, Kelly A Devereaux, et al.
Journal for Immunotherapy of Cancer|June 13, 2025
Phase II study of rucaparib and nivolumab in patients with leiomyosarcomaSujana Movva, Kenneth Seier, Martina Bradic, et al.
Pageof 3